FMP

FMP

Enter

CYTK - Cytokinetics, Incorp...

Financial Summary of Cytokinetics, Incorporated(CYTK), Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developi

photo-url-https://financialmodelingprep.com/image-stock/CYTK.png

Cytokinetics, Incorporated

CYTK

NASDAQ

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

55.98 USD

-0.32 (-0.572%)

About

ceo

Mr. Robert I. Blum

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activa...

CIK

0001061983

ISIN

US23282W6057

CUSIP

23282W605

Address

350 Oyster Point Boulevard

Phone

650 624 3000

Country

US

Employee

423

IPO Date

Apr 30, 2004

Summary

CIK

0001061983

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

23282W605

ISIN

US23282W6057

Country

US

Price

55.98

Beta

0.75

Volume Avg.

2.04M

Market Cap

6.42B

Shares

-

52-Week

25.98-110.25

DCF

-9.38

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-10.37

P/B

-

Website

https://www.cytokinetics.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest CYTK News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep